Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Quoin Pharmaceuticals Ltd

QNRX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.57

▲ +9.86%

Market Cap $21.81M · Vol 7.78K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$21.81M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+55.08%

YoY

RSI (14)

56.69

Momentum

Beta

1.75

vs Market

52W High

$23.50

80.55% below

52W Low

$3.25

40.62% above

Volume

7.78K

Avg 8.37K

P/B

57.68

Price-to-book

ROE

N/A

Return on equity

Free Float

95.27%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Quoin Pharmaceuticals Ltd (QNRX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does QNRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.01%

+0.22%

+5.30%

-29.48%

YTD

-68.33%

-59.98%

-96.76%

-99.99%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-15,804,660.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-87.56% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	57.68
P/FCF	N/A
EPS Growth	+55.08%
Outstanding Shares	168.15M

Technical Indicators

50-Day SMA	$5.42
200-Day SMA	$6.05
RSI (14)	56.69
Beta	1.75
52-Week High	$23.50
52-Week Low	$3.25

Volume Today	7.78K
Avg Daily Volume (30D)	8.37K
Relative Volume	0.93x
Volatility (10D)	53.12
Volatility (30D)	77.54
Free Float	95.27%

Analyst Consensus

BUY

Current Price $4.57

Mean Target $20.38

52W Low$3.25 52W High$23.50

Current

Target

$3.25 $23.50

Current Analyst target

+345.84% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00D9PB389

ISINUS74907L4095

CountryIsrael

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.53% ONC BeOne Medicines AG -0.33% 068270.KS Celltrion, Inc. +1.22% MEDP Medpace Holdings, Inc. -3.77% CRL Charles River Laboratories International, Inc. -4.44%

Company Profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.